GlaxoSmithKline plc (ADR) (GSK) was Upgraded by Jefferies to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Jefferies advised their investors in a research report released on Jul 14, 2016.
On the company’s financial health, GlaxoSmithKline plc (ADR) reported $0.18 EPS for the quarter, based on the information available during the earnings call on Feb 3, 2016. Analyst had a consensus estimate of $0.18. The company had revenue of $6286.00 million for the quarter, compared to analysts expectations of $6276.33 million. During the same quarter in the previous year, the company posted $0.27 EPS.
GlaxoSmithKline plc (ADR) opened for trading at $43.95 and hit $44.16 on the upside on Wednesday, eventually ending the session at $43.75, with a gain of 0.07% or 0.03 points. The heightened volatility saw the trading volume jump to 35,41,742 shares. Company has a market cap of $106,542 M.
GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSK’s Vaccines has a portfolio of over 30 paediatric adolescent adult travel vaccines. GSK’s Established Products Portfolio includes over 50 off-patent products as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories such as wellness oral health nutrition and skin health. Its brands include Sensodyne Panadol Horlicks Polident Paradontax Tums ENO NiQuitin/Nicorette Abreva Zovirax and Aquafresh. It operates in the United Kingdom the United States Belgium and China.